Is Monte Rosa Stock a Good Investment?
Monte Rosa Investment Advice | GLUE |
- Examine Monte Rosa's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Monte Rosa's leadership team and their track record. Good management can help Monte Rosa navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Monte Rosa's business and its evolving consumer preferences.
- Compare Monte Rosa's performance and market position to its competitors. Analyze how Monte Rosa is positioned in terms of product offerings, innovation, and market share.
- Check if Monte Rosa pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Monte Rosa's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Monte Rosa Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Monte Rosa Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Monte Rosa Stock
Researching Monte Rosa's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. Monte Rosa Therapeutics recorded a loss per share of 0.98. The entity had not issued any dividends in recent years.
To determine if Monte Rosa is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Monte Rosa's research are outlined below:
| Monte Rosa generated a negative expected return over the last 90 days | |
| Monte Rosa has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with loss before overhead, payroll, taxes, and interest of (37.24 M). | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Monte Rosa Therapeutics director Leo Chandra buys 58,383 in stock - Investing.com |
Monte Rosa uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Monte Rosa Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Monte Rosa's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Monte Rosa's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Monte Rosa's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.5408 | -0.43 | 0.1108 | 20 | ||
2024-11-07 | 2024-09-30 | -0.4709 | -0.29 | 0.1809 | 38 | ||
2024-12-31 | 2024-12-31 | 0.0269 | 0.27 | 0.2431 | 903 | ||
2024-03-14 | 2023-12-31 | -0.33 | -0.58 | -0.25 | 75 | ||
2022-03-29 | 2021-12-31 | -0.5 | -0.93 | -0.43 | 86 | ||
2021-08-12 | 2021-06-30 | -0.4 | -3.63 | -3.23 | 807 |
Monte Rosa Target Price Consensus
Monte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Monte Rosa's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Monte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Monte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Monte Rosa Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMonte Rosa Target Price Projection
Monte Rosa's current and average target prices are 5.42 and 16.00, respectively. The current price of Monte Rosa is the price at which Monte Rosa Therapeutics is currently trading. On the other hand, Monte Rosa's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Monte Rosa Target Price
Monte Rosa Analyst Ratings
Monte Rosa's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Monte Rosa stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Monte Rosa's financials, market performance, and future outlook by experienced professionals. Monte Rosa's historical ratings below, therefore, can serve as a valuable tool for investors.Know Monte Rosa's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Monte Rosa is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monte Rosa Therapeutics backward and forwards among themselves. Monte Rosa's institutional investor refers to the entity that pools money to purchase Monte Rosa's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aisling Capital Management Lp | 2024-12-31 | 1.5 M | Alphabet Inc | 2024-12-31 | 1.5 M | State Street Corp | 2024-12-31 | 1.1 M | Geode Capital Management, Llc | 2024-12-31 | 1 M | Citadel Advisors Llc | 2024-12-31 | 778.4 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 499.5 K | Norges Bank | 2024-12-31 | 445.9 K | Vestal Point Capital Lp | 2024-12-31 | 425 K | Northern Trust Corp | 2024-12-31 | 377 K | Nea Management Company, Llc | 2024-12-31 | 7.7 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 7.1 M |
Monte Rosa's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 358.6 M.Market Cap |
|
Monte Rosa's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.17) | (0.17) | |
| Return On Equity | (0.33) | (0.31) |
Determining Monte Rosa's profitability involves analyzing its financial statements and using various financial metrics to determine if Monte Rosa is a good buy. For example, gross profit margin measures Monte Rosa's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Monte Rosa's profitability and make more informed investment decisions.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.
Evaluate Monte Rosa's management efficiency
Monte Rosa Therapeutics has return on total asset (ROA) of (0.1366) % which means that it has lost $0.1366 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3615) %, meaning that it created substantial loss on money invested by shareholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -0.17. In addition to that, Return On Capital Employed is expected to decline to -0.3. The current year's Net Tangible Assets is expected to grow to about 327.7 M, whereas Total Assets are forecasted to decline to about 277.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.02 | 2.45 | |
| Tangible Book Value Per Share | 3.02 | 2.45 | |
| Enterprise Value Over EBITDA | (4.09) | (4.29) | |
| Price Book Value Ratio | 2.30 | 2.42 | |
| Enterprise Value Multiple | (4.09) | (4.29) | |
| Price Fair Value | 2.30 | 2.42 | |
| Enterprise Value | 331.4 M | 619.7 M |
Monte Rosa Therapeutics benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 1.496 |
Basic technical analysis of Monte Stock
As of the 26th of March, Monte Rosa secures the Mean Deviation of 3.58, risk adjusted performance of (0.05), and Standard Deviation of 4.82. Monte Rosa Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Monte Rosa Therapeutics variance and value at risk to decide if Monte Rosa Therapeutics is priced some-what accurately, providing market reflects its recent price of 5.42 per share. Given that Monte Rosa Therapeutics has information ratio of (0.07), we recommend you to check Monte Rosa's last-minute market performance to make sure the company can sustain itself at a future point.Monte Rosa's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monte Rosa insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monte Rosa's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monte Rosa insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Monte Rosa's Outstanding Corporate Bonds
Monte Rosa issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Monte Rosa Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Monte bonds can be classified according to their maturity, which is the date when Monte Rosa Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Monte Rosa's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Monte Rosa's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.58 | |||
| Coefficient Of Variation | (1,419) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.23 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 30.08 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 7.34 | |||
| Skewness | (0.48) | |||
| Kurtosis | 1.93 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.58 | |||
| Coefficient Of Variation | (1,419) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.23 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 30.08 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 7.34 | |||
| Skewness | (0.48) | |||
| Kurtosis | 1.93 |
Consider Monte Rosa's intraday indicators
Monte Rosa intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Monte Rosa stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 5.42 | |||
| Day Typical Price | 5.42 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.25) | |||
| Relative Strength Index | 57.32 |
Monte Rosa Corporate Filings
F4 | 25th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 4th of February 2025 Other Reports | ViewVerify |
Monte Stock media impact
Far too much social signal, news, headlines, and media speculation about Monte Rosa that are available to investors today. That information is available publicly through Monte media outlets and privately through word of mouth or via Monte internal channels. However, regardless of the origin, that massive amount of Monte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Monte Rosa news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Monte Rosa relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Monte Rosa's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Monte Rosa alpha.
Monte Rosa Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Monte Rosa can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Monte Rosa Corporate Management
| Filip MD | Chief Officer | Profile | |
| Jennifer Champoux | VP Operations | Profile | |
| Sharon Townson | Chief Officer | Profile | |
| Edmund Dunn | Senior Controller | Profile | |
| John Castle | Chief Scientist | Profile | |
| Magnus DPHIL | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Monte Rosa's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.